UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Evolving adoptive cellular therapies in urological malignancies

Wong, YNS; Joshi, K; Pule, M; Peggs, KS; Swanton, C; Quezada, SA; Linch, M; (2017) Evolving adoptive cellular therapies in urological malignancies. Lancet Oncology , 18 (6) E341-E353. 10.1016/S1470-2045(17)30327-3. Green open access

[img]
Preview
Text
Wong_Lancet review for RPS.pdf - Accepted version

Download (306kB) | Preview

Abstract

Immunotherapies have long been used to treat urological cancers but rarely lead to cure. In the past 5 years, success of immune checkpoint inhibition has led to a resurgence of enthusiasm for immunotherapy in the treatment of solid tumours. Increased understanding of tumour immune biology, technological advancements of gene transfer and cell culture, and improved clinical infrastructures for routine delivery of cell products, has made cell-based immunotherapeutics a real prospect for cancer therapy. These scientific and clinical activities, attempting to exploit the innate and adaptive immune systems for therapeutic gain, are well exemplified by the urological malignancies of renal, bladder, prostate, and penile cancer, a group of anatomically localised diseases, each with a distinct biology and different immunotherapeutic challenges. In this Review, we present the results of clinical studies investigating autologous cellular therapies in urological malignancies. Specifically, we discuss the rationale for upcoming studies, and how novel therapies and adoptive cell combinations can be used for personalised cancer therapy.

Type: Article
Title: Evolving adoptive cellular therapies in urological malignancies
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/S1470-2045(17)30327-3
Publisher version: https://doi.org/10.1016/S1470-2045(17)30327-3
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Science & Technology, Life Sciences & Biomedicine, Oncology, TUMOR-INFILTRATING LYMPHOCYTES, RESISTANT PROSTATE-CANCER, ENGINEERED T-CELLS, PHASE-III TRIAL, ANTIGEN RECEPTOR, IMMUNE-RESPONSE, BLADDER-CANCER, RECOMBINANT INTERLEUKIN-2, CHECKPOINT BLOCKADE, KINASE INHIBITORS
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10049346
Downloads since deposit
136Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item